Nurix Therapeutics
Nurix Therapeutics' revenue rose 54.0% to $84 million in fiscal 2025. Its operating margin was −340.2%, up from −390.5% a year earlier. Free cash flow was −$263 million. The diluted share count rose 29.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Nurix Therapeutics does
Nurix Therapeutics is a clinical-stage drug company that develops medicines based on targeted protein degradation. This approach is meant to mark harmful proteins for the cell's own disposal system rather than just block them. It targets cancer and inflammatory diseases and has not sold a product. It says its discovery engine uses machine learning.
Its own pipeline has three candidates in human trials: bexobrutideg, a degrader of a protein called BTK; zelebrudomide, which degrades BTK and two other proteins; and NX-1607, which blocks a protein called CBL-B that restrains immune cells. It also has earlier degraders in preclinical work.
Nurix also works with partners. Under collaborations with Gilead Sciences, Sanofi and Pfizer it has a partnered pipeline that includes a degrader of IRAK4, and for some candidates it keeps options to share in development, sales and profits in the United States. It has never earned revenue from product sales.
Its biggest risks, as it describes them
- It has lost money since it began and may never be profitable.
- It will need a lot more funding, which could dilute shareholders.
- Its protein degradation approach is unproven.
- Drug development is long and costly, and early trial results may not predict later ones.
- Side effects found in trials could slow or stop development.
Income statement
Nurix Therapeutics lost money in fiscal 2025: a net loss of $264 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 296 | 309 | 288 | 610 | 593 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.7x | 4.5x | 3.4x | 6.5x | 7.0x |
| Quick ratio | 4.7x | 4.5x | 3.4x | 6.5x | 7.0x |
Cash flow
Projections
Project Nurix Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Nurix Therapeutics shares on the open market, and 3 insiders sold $4.2 million, $3.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Christine RingChief Legal Officer | Sold plan | 5,787 | $25.76 | $149,048 | Form 4 |
| Sep 1, 2026 | Gwenn HansenChief Scientific Officer | Sold plan | 1,452 | $25.47 | $36,982 | Form 4 |
| Aug 5, 2026 | Gwenn HansenChief Scientific Officer | Sold plan | 4,356 | $25.00 | $108,900 | Form 4 |
| Aug 4, 2026 | Houte Hans vanChief Financial Officer | Sold plan | 4,761 | $24.36 | $115,995 | Form 4 |
| Aug 4, 2026 | Gwenn HansenChief Scientific Officer | Sold plan | 4,111 | $24.36 | $100,140 | Form 4 |
| Aug 3, 2026 | Christine RingChief Legal Officer | Sold plan | 16,589 | $23.05 | $382,376 | Form 4 |
| Jul 30, 2026 | Gwenn HansenChief Scientific Officer | Sold | 3,847 | $23.38 | $89,943 | Form 4 |
| Jul 30, 2026 | Houte Hans vanChief Financial Officer | Sold | 2,845 | $23.38 | $66,516 | Form 4 |
| Jul 2, 2026 | Christine RingChief Legal Officer | Sold plan | 11,008 | $23.56 | $259,348 | Form 4 |
| Jun 25, 2026 | Christine RingChief Legal Officer | Sold plan | 28,935 | $20.06 | $580,436 | Form 4 |
| Jun 25, 2026 | Gwenn HansenChief Scientific Officer | Sold plan | 5,394 | $20.00 | $107,880 | Form 4 |
| Jun 2, 2026 | Christine RingChief Legal Officer | Sold plan | 8,148 | $16.60 | $135,257 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −17.3% | −362.5% | −259.8% |
| Altman Z'' | −2.72 | 3.28 | 1.20 |
| Accruals ratio | −16.2% | −4.1% | −2.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Nurix Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics | FY25 | 54.0% | −340.2% | −313.7% | — | — | — | |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | Compare |
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | Compare |
| Zymeworks | FY25 | 38.9% | −87.3% | −32.6% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 31 | 18 | 30 | 39 | 77 | 54 | 84 |
| Revenue growth | — | −42.7% | 67.0% | 29.8% | 99.3% | −29.1% | 54.0% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 45 | 66 | 116 | 184 | 189 | 222 | 317 |
| Operating income | −22 | −65 | −118 | −184 | −155 | −213 | −286 |
| Net income | −22 | −43 | −117 | −180 | −144 | −194 | −264 |
| Diluted EPS (US$) | −6.59 | −2.76 | −2.73 | −3.71 | −2.65 | −2.88 | −3.05 |
| Diluted shares (millions) | 3 | 16 | 43 | 49 | 54 | 67 | 87 |
| Cash flow | |||||||
| Cash from operations | 1 | −0 | −84 | −160 | −81 | −173 | −250 |
| Capital expenditure | 2 | 5 | 6 | 12 | 8 | 9 | 14 |
| Free cash flow | −1 | −5 | −90 | −172 | −90 | −182 | −263 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 4 | 16 | 28 | 34 | 34 | 38 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 38 | 281 | 296 | 309 | 288 | 610 | 593 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 44 | 396 | 477 | 417 | 356 | 669 | 688 |
| Total liabilities | 54 | 106 | 134 | 113 | 155 | 142 | 149 |
| Shareholders' equity | −58 | 290 | 342 | 304 | 200 | 527 | 539 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −71.5% | −364.7% | −396.3% | −476.0% | −201.4% | −390.5% | −340.2% |
| Net margin | −69.7% | −242.7% | −393.9% | −466.9% | −187.0% | −354.9% | −314.9% |
| Free cash flow margin | −3.4% | −26.0% | −302.6% | −445.4% | −116.6% | −333.4% | −313.7% |
| Rule of 40 (growth + FCF margin) | — | −68.7% | −235.7% | −415.6% | −17.3% | −362.5% | −259.8% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −37.2% | −37.0% | −55.8% | −57.1% | −53.2% | −49.6% |
| Return on assets | — | −19.6% | −26.9% | −40.4% | −37.3% | −37.8% | −39.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — |